Biggest difference IMO:
ADVEXIN delivers p53 directly to tumor cell region via injection to the site, through a courier vector modified nonreplicating Adnovirus. The p53 is grafted into the genetic material of a virus which then enters a human host cell and releases p53. So, ADVEXIN is modified Adnovirus particle with a p53 segment spliced into its genetic structure.
KEVETRIN, on the other hand, is delivered via IV and once circulating in a patient enters individual cells via normal cellular pathways. Once inside, it appears to directly act upon and repair p53 and restart the apoptosis mechanism that instructs mutated cells to die. Both enter healthy cells and both have no effect. However, KEVETRIN's delivery to target cancer cells requires no extraordinary vectors for therapeutic delivery.
An important point, ADVEXIN shows adverse effects in more than 1/3ed of all tested subjects, though it is still considered "well tolerated" by oncological therapy standards. In one successful case of full remission, therapy went on for 8 years with almost 300 administrations (more than twice a month for 8 years) for that one patient. This patient is considered ADVEXIN's best result.
